🚨Breaking News: New ESC Guidelines on CCS. Intracoronary Imaging now Class IA for LM, true bifurcation and long lesions! Either OCT or IVUS. @PCRonline @escardio @NielsRHolm @twj1974 @nicolasamabile @FBiccire @ziadalinyc @hect2701 @sbrugaletta @HolgerNef

Most viewed in the last 7 days from @JAMACardio: What are the effects of lowering low-density lipoprotein cholesterol in nonculprit coronary segments with advanced atherosclerotic features? https://t.co/EEzqvNQViF

Long-term effect of biodegradable vs durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction. Read the CONNECT trial in EHJ. https://t.co/H4ikU5sHMI #STEMI #neoatherosclerosis #cardiotwitter @ESC_Journals @escardio

Editorial by Prof Steven Nissen @CleClinicHVTI https://t.co/UFKeejUBA0

#PCSK9i plus high-intensity statin therapy achieves 2% plaque burden regression at vessel level 5% PB regression at LESION level 10% PB regression at the most narrow (MLA) vessel spot Just published @JAMACardio @FBiccire https://t.co/uso9hkHQ4W

thanks @EricTopol for the interest in our plaque regression study with PCSK9i. The key point is that the level of plaque regression achieved in vessels is 2% (known already from main trial) but much more @ lesion level (5%) and at the most narrow spot of the vessel (10%).

AI based plaque characterization/quantification (AI QCT) of a #CCTA dataset (2000 patients referred for CAD evaluation in Turku, FIN) 7 YRS Fup treated medically shows that plaque burden and plaque composition accurately predicts future ACS events.Congratulations to @BaerSarah_

New #ESC guidelines on AFIB. New Class IB recommendation for surgical LAAC in patients undergoing open heart surgery. No change for percutaneous LAAC despite Prague RCT (II b), unlike AHA /ACC Guidelines (IIa). Reflects the much lower uptake of LAAC in EU. @PCRonline @escardio

New ESC CCS Guidelines on CCS. Longterm single antiplatelet tx with Clopidogrel now Class IB. Low dose Colchicine and GLP 1 RA lass IIb. @PCRonline @escardio

New ESC hypertension guidelines: Class IIb for renal denervation in treatment resistant arterial hypertension despite RCT evidence from sham controlled trials. @escardio @PCRonline #ESCLondon

Interested in incorporating routine CCT into your LAAO practice? Check out the latest expert consensus 📝 on the use of CCT post LAAO published today #JACCINT https://t.co/TM1O2TwDan

🚨 Rethink #Anomalous Aortic Origin of Coronary Artery #AAOCA + #interarterial course. 🚫No 'scissor-like' compression (unidirectional intramural compression by the aorta) 🚫Not all ‚malignant‘ (relevant) @RaberLorenz @biglermarius @snsf_ch @EHJCREiC https://t.co/gm9kePQjPx

🚨 New ELAPSE Trial Site Alert! 🚨 The Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne has officially opened today as the newest site in Switzerland for the ELAPSE trial and is now recruiting patients! @StrokeBern @RaberLorenz @FishingNeurons @DavidSeiffge

@DavidSeiffge @ELAPSETrial @FishingNeurons @RaberLorenz @StrokeBern @TotoMynell @MASStroke I strongly encourage all physicians to enroll AFib patients who had an ischemic stroke despite anticoagulant use into the @ELAPSETrial - the RCT focusing on this population

Congratulations to @BaerSarah_ for her successful PhD thesis defense @ Turku University, Finnland on the topic of CV imaging, led by @JuhaniKnuuti. Looking forward to have you back @inselgruppe @BernCVRC

Fantastic progress with the ELAPSE trial, an @snf_ch supported IIT. Topic: LAAC/NOAC vs NOAC alone in breakthrough stroke patients.

Thanks to @unibern, our recent @TheLancetNeuro review on secondary stroke prevention in people with AF is now #openaccess! @FishingNeurons @RaberLorenz @UCLStrokeRes @caso_valeria @v_cancelloni @ESOstroke @WorldStrokeOrg @StrokeBern @MASStroke https://t.co/EechwFQ4VV

If you want to know more about pericardial effusion LAAC-related read our original research paper just published on Jacc Intv @RaberLorenz @DavidSeiffge @JACCJournals @BernCVRC

🫀 Does Alirocumab affect #platelet function in patients with #MI? ⤵️ 📌 Among pts. receiving DAPT in the PACMAN-AMI Trial, #Alirocumab had no significant effect on platelet reactivity In TH current issue 👉 https://t.co/XEUv3Seh2w #PCSK9 #CardioTwitter @RaberLorenz

Secondary stroke prevention in people with AF - published ⁦@TheLancetNeuro⁩! fantastic team work @caso_valeria⁩ ⁦@RaberLorenz⁩ ⁦@FishingNeurons⁩ ⁦@UCLStrokeRes⁩ ⁦@Ash_Shoamanesh⁩ ⁦@ESOstroke⁩ ⁦@StrokeBern⁩